Explores GLP-1 receptor agonists’ effects on metabolic control in type 1 diabetes, suggesting a new treatment option.
Metabolic control in type 1 diabetes (T1D) remains challenging. Despite advances in insulin therapies and technology,1 most individuals fail to achieve glycaemic targets and remain at risk of hypoglycaemia, high glucose variability, ketoacidosis, weight gain, oxidative stress, and cardiovascular/renal complications. Disrupted intra-islet insulin regulation of glucagon secretion also leads to hyperglucagonaemia.2
No takes yet. Share an insight, caveat, or question.
Dimitriadis et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: